On April 2, 2026, CMS finalized the Contract Year 2027 rule, and the headline number is real: the Medicare Advantage Star Ratings measure set loses 11 measures. The agency frames the cuts as a clean-up, pulling out measures tied to administrative process and to areas where plans perform so uniformly well that beneficiaries cannot tell them apart. The rule is effective June 1, 2026, with most provisions applying to coverage beginning in 2027.
Here is the part that should make a VP of Quality sit up. “Simplification” is not neutral. When you remove measures where almost everyone scores high, you remove the measures that were quietly propping up the strong performers. The plans most exposed to a downward move are often the ones that had been banking points on exactly those low-variation measures. A leaner measure set is a higher-stakes one, and the strategy that worked under the old list will not survive the new one unchanged.
What actually changed
CMS finalized the removal of 11 measures, down from the 12 it proposed in November 2025. The diabetes care eye exam measure survived the comment period and stays in after plans pushed back. Most removals begin with the 2027 measurement year, and two are specifically effective for the 2028 Star Ratings: the Call Center Foreign Language Interpreter and TTY Availability measure, and the Statin Therapy for Patients with Cardiovascular Disease measure on the Part C side.
The agency also declined to implement the Excellent Health Outcomes for All reward, the program previously known as the Health Equity Index, which had been finalized under the prior administration for the 2027 ratings. Instead, CMS will continue the historical reward factor, the same mechanism it has used since 2009 to reward consistently high performance across all enrollees and all measures. This is a continuation, not a reinstatement. The reward you already know stays in place, and the equity reward that was scheduled to arrive does not.
CMS also added one measure even as it cut 11. A new Part C depression screening and follow-up measure enters with the 2027 measurement year and the 2029 Star Ratings. More on that below, because it matters more than its single slot suggests.
One operational detail is easy to miss: plans must continue reporting on the removed measures through CMS’s online plan comparison tools, even though those measures no longer factor into the rating. Removed from the score does not mean removed from your reporting obligations.
The reward factor reversal is where the money is
Most of the coverage led with the measure cuts. The bigger financial story is the reward factor.
CMS estimates the net effect of the Star Ratings changes on the Medicare Trust Fund at roughly $18.6 billion from 2027 through 2036, about 0.21 percent of total payments to plans over that window. That figure rose from the proposed rule, where CMS had estimated closer to $14 billion. The increase is not an accounting quirk. The dominant driver is the decision to continue the existing reward factor rather than replace it with the Health Equity Index. Keeping the broad, all-enrollee reward in place, instead of redirecting it toward a narrower equity calculation, pushes more dollars to high performers across the board.
The practical read for a quality leader is that the rule, on balance, is expected to lift ratings and the bonus dollars attached to them for many plans. That is good news if you are already strong. It is a warning if you are not, because a rising tide that lifts your competitors raises the bar you are measured against.
It is not only about measures
The Star Ratings changes are the part that hits your quality program directly, but the CY2027 rule is broad. It pursues a wider deregulatory agenda, rolling back some of the marketing and enrollment safeguards introduced in 2023, with marketing and communications changes taking effect October 1, 2026, and it tightens guardrails around supplemental benefits while adding new program integrity requirements. None of that changes your measure strategy, but it does mean the rule lands on several desks in your organization at once. If you are coordinating the Stars response, expect adjacent operational changes moving on their own timelines, and make sure the left hand knows what the right is doing.
Why a leaner measure set is not a safer one
The instinct is to read “fewer measures” as “less work.” The math says the opposite. A smaller denominator means every measure that remains carries more relative weight in your overall rating. The cushion you had from a deep bench of easy, high-scoring measures is thinner now. A single outcome measure that slips can move the needle further than it would have a year ago.
CMS projects that most contracts, around 63 percent, see no change to their overall rating from these adjustments. That is cold comfort if you are in the share that moves. In its proposed-rule analysis, CMS had estimated that roughly a quarter of contracts would drop by a half star while a smaller share would gain, and it is the high-baseline plans, the ones leaning on low-variation measures, that are most likely to feel the floor shift. The contracts that treat “63 percent unchanged” as reassurance are exactly the ones that should be modeling whether they are in the other 37 percent.
Make it concrete. Imagine a plan that has held a strong overall rating for years, partly on the strength of a cluster of administrative and access measures where nearly every plan scores at or near the top. Those measures contributed steady points and almost no risk. Several of them are gone now. The plan’s clinical and outcome performance has not changed, but its rating math has, because the dependable, low-risk points it quietly relied on are no longer in the formula. Nothing about its care got worse. Its exposure went up anyway. That is the trap of reading a shorter list as a lighter load.
The HEDIS angle most plans are underweighting
A large share of the clinical measures in the Star Ratings come from NCQA’s HEDIS measure set. That is not a side note. It means two transitions are landing on your quality program at the same time, and they interact.
The CY2027 rule changes which measures count and how much each one weighs. Separately, NCQA is moving its HEDIS measures to a fully digital model, retiring the hybrid method by measurement year 2029 and publishing measure logic in FHIR and CQL on the way to a fully digital state by 2030. So the plans that come out ahead are not just re-baselining against a shorter Star list. They are also rebuilding the data pipeline that produces the underlying HEDIS rates. Treating those as one coordinated program, rather than two disconnected fire drills, is the difference between getting ahead of the next three cycles and reacting to them.
There is a second-order effect worth naming. As NCQA’s HEDIS measures move to published FHIR and CQL logic, the room for interpretation shrinks, which means your reported rates become more directly comparable to everyone else’s and more exposed to audit. A number you cannot trace back to the source claim or the clinical event that produced it is a liability in that world, not just an inconvenience. The plans that pair a re-baselined Star strategy with a clean, traceable HEDIS data pipeline will be the ones that can defend their rates when someone asks how they got them. In a tighter measure set, where each remaining measure carries more weight, someone will ask.
The new behavioral health measure deserves your attention now
In the same rule where CMS pulled 11 measures, it added the first Star measure built specifically around behavioral health. Starting with the 2027 measurement year and the 2029 Star Ratings, a new Part C measure tracks the share of members screened for clinical depression using a standardized instrument and, for those who screen positive, whether they receive timely follow-up. CMS has indicated it will display the screening and follow-up rates separately and average the two when scoring the measure, and that the addition aligns with U.S. Preventive Services Task Force recommendations while filling a long-standing gap, since the program has had no measure specific to behavioral health.
This one lands on two desks at once. The VP of Quality owns the rating exposure. The Chief Medical Officer and the care teams own the clinical workflow that actually produces the result, because the screening happens in an encounter and the follow-up is a clinical action, not a plan-side outreach campaign. If those two owners are not coordinated well before 2027, this measure becomes a finger-pointing exercise after the year closes. If they are, it is a rare opportunity: a measure where almost everyone starts from a low base and the early movers can build a durable lead.
What it means if you hold a value-based contract
For a Chief Medical Officer in a value-based arrangement, the rule shifts the terrain in a specific way. The measures that survived skew toward clinical outcomes, the exact territory where good care and good scores are supposed to line up. That is an opportunity, because the work that helps the patient is increasingly the same work that protects the contract. It is also a demand, because outcome measures are harder to move than administrative ones, and they depend on what happens in the exam room, not on a plan-side mailing.
The depression screening measure is the clearest example. The follow-up that determines the numerator is a clinical workflow your teams own, and so is the documentation that proves it happened. A provider group that builds these into the encounter now, rather than bolting them on in 2027, turns a looming measure into a head start, and does it on work that genuinely helps patients the program has been blind to.
What to do with this
Three moves for the next planning cycle, and a fourth for the budget conversation.
First, re-baseline. Pull the 11 removed measures out of your model and recompute where you actually stand on the surviving set under the current weights. Your real exposure is hiding in that recompute, and a spreadsheet built on last year’s measure list will lie to you with total confidence.
Second, re-weight your improvement spend. The dollars you were spending to defend a low-variation administrative measure are now free. Redirect them toward the clinical and outcome measures that carry more weight and more genuine variation, because that is where rating movement now lives and where a competitor cannot catch you in a single cycle.
Third, get in front of the depression screening measure. The measurement year is 2027 and the rating does not land until 2029, which is a generous runway for a measure where the work is operational, capturing the standardized screening as structured data and building the follow-up into the clinical workflow. The plans that start now will not be reverse-engineering their behavioral health data the year it counts.
Fourth, connect the rating to dollars before you ask for budget. With the rule expected to lift ratings and bonuses for many plans, the ones that gain ground will be those that can say, in the language a CFO speaks, what a specific half star is worth against next year’s revenue. Walk into the budget conversation with that number, not with a measure name.
The honest version
A rule that “simplifies” the program can still cost you a half star, and a half star is not a rounding error when it sits on top of the bonus dollars tied to your rating. The plans that come out ahead will be the ones that treat this as a re-baselining event, not a paperwork update. That starts with knowing precisely where you stand on the measures that remain, traced back to the data, with no guessing and no black box. That clarity, from the source row to the star, is the entire reason we build the way we do.
HEDIS is a registered trademark of the National Committee for Quality Assurance.